In the interest of supporting regulatory professionals addressing the unprecedented public health threat posed by COVID-19, AgencyIQ will be sharing all content concerning the virus and its regulatory implications on this page as the situation evolves. To learn about AgencyIQ and see more of our coverage of FDA, please contact us:
COVID-19 Drug and Vaccine Development Tracker
The pharmaceutical and biopharmaceutical industry is engaged in an unprecedented search for products to potentially treat, cure or prevent COVID-19. AgencyIQ has reviewed ClinicalTrials.gov, company announcements and media reports to provide a detailed landscape of the COVID-19 development pipeline.
Latest AgencyIQ COVID-19 Analysis
COVID Weekly Recap: FDA looking to develop additional standards for COVID-19; WHO issues standards for emergency use of vaccines
Top stories: · FDA wants to set standards for COVID-19-related viral pneumonia treatment processes · Real-world evidence for the COVID-19 vaccine: Understanding bias and tracking
COVID Weekly Recap: The need for transparency in COVID development. International COVID test standard on its way. COVID shows the need for a quality rating system.
Top stories: · Development secrecy vs. a public’s right to know: An argument erupts · IVD Chief: International COVID test standard likely available by end
COVID Weekly Recap: FDA rejects Oleandrin as a supplement. Legislators probe FDA on transparency.
Top stories: FDA denies new dietary ingredient application for Oleandrin. Legislation seeks to bolster public confidence in FDA vaccine decision with transparency. Legislators question communications
COVID Weekly Recap: A significant change to FDA’s authority over laboratory tests. New guidance on FDA inspections. FDA clarity on diagnostic and face mask policies.
Top stories: FDA officially schedules its AdComm for COVID vaccines. Convalescent plasma has a diagnostics problem. FDA still silent on HHS’ laboratory developed test policy.
COVID Weekly Recap: A significant change to FDA’s authority over laboratory tests. New guidance on FDA inspections. FDA clarity on diagnostic and face mask policies.
Top stories: HHS unveils new approach for FDA’s oversight of laboratory developed tests. FDA releases details about its facility inspections during COVID. Congress wants
COVID Weekly Recap: FDA commits to a COVID advisory committee and political independence
Top stories: FDA says its Advisory Committee will review COVID vaccines. What Russia’s approval of a vaccine means for the FDA. FDA Commissioner says political
The FDA’s Complete Response Letter secrecy could be on a crash course with COVID
FDA regulators have long thought about ways to make Complete Response Letters more transparently available to both the public and industry. Now, interest in developing
Socially distant generic litigation: How COVID could slow FDA approvals
Generic drug approval applications that rely on the Paragraph IV certification process to invalidate patents may experience delays as courts contend with COVID-19 delays. What
3D printing during COVID tests FDA’s policies
The FDA has leaned on 3D printing to help alleviate shortages of essential medical equipment during COVID-19, but the broader use of the technology poses
FDA clarifies “moderate” changes for already-approved devices under new COVID guidance
Manufacturers of Class III or Humanitarian Device Exemption (HDE)-eligible medical devices could see increased flexibility to keep manufacturing capacity up amid the pandemic under new
As COVID restricts FDA travel, could its quality metrics proposal make a comeback?
After initially receiving negative feedback on its proposal to implement a quality metrics reporting program, the FDA’s proposed 2016 program could represent an effective means
FDA provides further clarity on clinical trial adverse event reporting
Newly updated guidance from the FDA provides sponsors with additional details about how to report adverse events associated with COVID-19. By Kedest Tadesse, MS,
House COVID package looks to make improvements to shortage reporting and the supply chain
After the passage of the CARES Act in March, legislators in Congress are still working on packages to respond to the COVID-19 pandemic. The House’s
FDA responds to additional concerns about protocol modification due to COVID-19
COVID-19 has complicated the clinical trial landscape, in some cases requiring protocol deviations to ensure the integrity of the trial and patient safety. AgencyIQ explores
FDA releases long-awaited guidance on COVID-19 drug development
The guidance, intended to support companies racing to develop treatments for the novel coronavirus, outlines best practices for designing clinical trials that the FDA will
